04.05.2021 • News

K+S Closes Americas Salt Sale to Stone Canyon

German potash and salt producer K+S has completed the sale of its Americas salt business to US-based global industrial holding company Stone Canyon Industries Holdings. Burkhard Lohr, chairman of the board of executive directors at K+S, said the transaction is a major step toward reducing the company’s debt.

The Americas business comprises K+S Chile, acquired in 2006 and formerly known as SPL, Morton Salt (USA), acquired in 2009, as well as Windsor Salt (Canada). Taking into account debt and cash, the purchase price was roughly €2.6 billion.

Stone Canyon will integrate the newly acquired assets into Kissner Group Holdings, which it bought in 2020. Headquartered in Overland Park, Kansas, Kissner produces bulk, specialty and evaporated salt for customers across the US and Canada. Going forward, the K+S Americas business will be known as Morton Salt.

The sale’s closure on Apr. 30 followed antitrust clearance by the US Department of Justice on Apr. 19. However, in order to get the deal approved, Stone Canyon has to divest its US Salt subsidiary in Watkins Glen, New York.

Author: Elaine Burridge, Freelance Journalist

German potash and salt producer K+S has completed the sale of its Americas salt...
German potash and salt producer K+S has completed the sale of its Americas salt business to US-based global industrial holding company Stone Canyon Industries Holdings. The sale’s closure on Apr. 30 followed antitrust clearance by the US Department of Justice on Apr. 19. (c) K+S

Special Issue

Circular Plastics Economy
Explore the Future of Plastics

Circular Plastics Economy

This special CHEManager issue explores the industry’s pivotal shift towards a more sustainable, circular plastics value chain. Readers will find expert analysis and real-world solutions for today’s most pressing recycling and regulatory challenges.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read